Stocks Health care RDY
NYSE · Health careDR Reddys Laboratories Ltd (RDY)
DR Reddys Laboratories Ltd reported revenue of $3.8B in fiscal 2025, up 13.8% from a year earlier. Net income was $663M, a net margin of 17.4%. Operating cash flow minus capital spending left $223M of free cash flow in fiscal 2025. At March 31, 2025 it held $172M in cash.
Key facts about DR Reddys Laboratories Ltd
- Net worth
- DR Reddys Laboratories Ltd has a market value (market cap) of $12.4B at the latest share price, and shareholders' equity of $3.9B on its balance sheet at March 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $3.8B (+13.8% year on year), with net income of $663M.
- Cash flow
- In fiscal 2025 operations brought in $545M of cash; after $322M of capital spending, free cash flow was $223M.
What DR Reddys Laboratories Ltd does
DR Reddys Laboratories Ltd is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker RDY.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $3.8B | $663M | $0.79 | $223M |
| 2024 | $3.4B | $668M | $4.01 | $348M |
| 2023 | $3B | $548M | $3.30 | $578M |
| 2022 | $2.8B | $311M | $1.87 | $177M |
| 2021 | $2.6B | $236M | $1.52 | $355M |
| 2020 | $2.3B | $259M | $1.56 | $332M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where RDY ranks in Health care
Dividends
It paid out $78M in cash dividends, 12% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | n/a | $78M | 12% |
| 2024 | n/a | $80M | 12% |
| 2023 | n/a | $61M | 11% |
| 2022 | n/a | $55M | 18% |
| 2021 | n/a | $57M | 24% |
| 2020 | n/a | $52M | 20% |
Latest SEC filings
What DR Reddys Laboratories Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026
- November 4, 2026
- October 29, 2026
- October 29, 2026
- October 26, 2026
- October 26, 2026
- October 23, 2026
- October 23, 2026
- October 23, 2026
- October 23, 2026
Insider trades
What the people running DR Reddys Laboratories Ltd did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns RDY
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| K. Satish Reddy13D, may seek influence with 5 related filers | 13.58% | September 18, 2025 |
| Mr. G.V. Prasad13D, may seek influence with 2 related filers | 13.04% | July 1, 2024 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 238 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Robeco Institutional Asset Management B.V. | 18,021,100 | +843,218 |
| Morgan Stanley | 10,936,320 | +1,564,726 |
| BlackRock, Inc. | 10,585,742 | -1,001,385 |
| Royal Bank of Canada | 9,213,269 | -770,813 |
| Aikya Investment Management Ltd | 8,493,852 | +494,056 |
| Renaissance Technologies LLC | 7,347,028 | -512,700 |
| Dimensional Fund Advisors LP | 5,312,065 | -11,183 |
| Jpmorgan Chase & Co | 4,069,357 | -302,021 |
| State Street Corp | 4,124,686 | +98,479 |
| Alliancebernstein L.P. | 3,730,713 | +1,188,824 |
| Vanguard Capital Management LLC | 3,100,911 | 0 |
| Franklin Resources Inc | 2,844,583 | -11,511 |
| Nuveen, LLC | 2,827,699 | new |
| Bnp Paribas Financial Markets | 2,649,866 | -534,105 |
| Marshall Wace, Llp | 2,025,356 | -638,950 |
| American Century Companies Inc | 1,830,883 | +169,550 |
| Schroder Investment Management Group | 1,618,404 | +1,437,165 |
| UBS Group AG | 1,658,536 | +106,228 |
| Vanguard Portfolio Management LLC | 1,522,361 | -251,377 |
| Creative Planning | 1,240,848 | +73,666 |
Insiders
Questions about RDY
What does DR Reddys Laboratories Ltd do?
DR Reddys Laboratories Ltd is a company in the Health care sector, listed on NYSE as RDY. Its shares trade on NYSE under the ticker RDY.
What is DR Reddys Laboratories Ltd's net worth?
DR Reddys Laboratories Ltd has a market value (market cap) of $12.4B at the latest share price, and shareholders' equity of $3.9B on its balance sheet at March 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is DR Reddys Laboratories Ltd profitable?
Yes. In fiscal 2025 it reported net income of $663M on revenue of $3.8B, a net margin of 17.4%.
How much revenue does DR Reddys Laboratories Ltd make?
In fiscal 2025 DR Reddys Laboratories Ltd reported revenue of $3.8B. That is 13.8% more than a year earlier.
When did DR Reddys Laboratories Ltd last report?
Its newest filing of any kind is the foreign issuer update from November 5, 2026.
Similar companies
Compare RDY with
Follow RDY
Get an email when DR Reddys Laboratories Ltd files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values DR Reddys Laboratories Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.